Supernus Pharmaceuticals Cash on Hand 2011-2024 | SUPN

Supernus Pharmaceuticals cash on hand from 2011 to 2024. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Supernus Pharmaceuticals Annual Cash on Hand
(Millions of US $)
2023 $255
2022 $461
2021 $340
2020 $423
2019 $347
2018 $356
2017 $140
2016 $90
2015 $62
2014 $74
2013 $82
2012 $89
2011 $49
2010 $
Supernus Pharmaceuticals Quarterly Cash on Hand
(Millions of US $)
2024-09-30 $403
2024-06-30 $347
2024-03-31 $298
2023-12-31 $255
2023-09-30 $200
2023-06-30 $152
2023-03-31 $632
2022-12-31 $461
2022-09-30 $392
2022-06-30 $361
2022-03-31 $312
2021-12-31 $340
2021-09-30 $444
2021-06-30 $410
2021-03-31 $391
2020-12-31 $423
2020-09-30 $352
2020-06-30 $375
2020-03-31 $401
2019-12-31 $347
2019-09-30 $297
2019-06-30 $259
2019-03-31 $293
2018-12-31 $356
2018-09-30 $280
2018-06-30 $174
2018-03-31 $490
2017-12-31 $140
2017-09-30 $115
2017-06-30 $93
2017-03-31 $87
2016-12-31 $90
2016-09-30 $80
2016-06-30 $60
2016-03-31 $45
2015-12-31 $62
2015-09-30 $58
2015-06-30 $70
2015-03-31 $65
2014-12-31 $74
2014-09-30 $73
2014-06-30 $47
2014-03-31 $59
2013-12-31 $82
2013-09-30 $87
2013-06-30 $103
2013-03-31 $70
2012-12-31 $89
2012-09-30 $61
2012-06-30 $77
2012-03-31 $38
2011-12-31 $49
2011-09-30
2011-06-30
2011-03-31
2010-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $1.962B $0.608B
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.044B 6.25
Dr Reddy's Laboratories (RDY) India $11.978B 22.92
BridgeBio Pharma (BBIO) United States $4.260B 0.00
Bausch Health Cos (BHC) Canada $3.012B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.097B 12.61
Taysha Gene Therapies (TSHA) United States $0.434B 30.29
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00